{"id":"active-comparator-folfox-plus-cetuximab","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Neutropenia"},{"rate":"30-40","effect":"Diarrhea"},{"rate":"30-40","effect":"Nausea/vomiting"},{"rate":"20-30","effect":"Peripheral neuropathy"},{"rate":"80-90","effect":"Acneiform rash"},{"rate":"20-30","effect":"Anemia"},{"rate":"20-30","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FOLFOX is a chemotherapy regimen (fluorouracil, leucovorin, and oxaliplatin) that damages DNA and inhibits cell division. Cetuximab is a monoclonal antibody that binds to epidermal growth factor receptor (EGFR) on cancer cells, blocking growth signaling and enhancing immune-mediated cell death. Together, they provide synergistic anti-tumor activity in EGFR-expressing colorectal cancers.","oneSentence":"FOLFOX plus cetuximab combines chemotherapy with an EGFR-targeting monoclonal antibody to kill colorectal cancer cells through dual mechanisms of DNA damage and growth factor receptor inhibition.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:59:14.146Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer, KRAS wild-type"},{"name":"Locally advanced colorectal cancer"}]},"trialDetails":[{"nctId":"NCT07389265","phase":"PHASE3","title":"Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2025-10-01","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":480},{"nctId":"NCT05074966","phase":"PHASE3","title":"The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2021-09-06","conditions":"Colo-rectal Cancer","enrollment":314}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Active Comparator: FOLFOX plus cetuximab","genericName":"Active Comparator: FOLFOX plus cetuximab","companyName":"Chinese Academy of Medical Sciences","companyId":"chinese-academy-of-medical-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FOLFOX plus cetuximab combines chemotherapy with an EGFR-targeting monoclonal antibody to kill colorectal cancer cells through dual mechanisms of DNA damage and growth factor receptor inhibition. Used for Metastatic colorectal cancer, KRAS wild-type, Locally advanced colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}